RATIONALE: Type 2 diabetes mellitus is a major risk factor for the development of active tuberculosis, although the biological basis underlying this susceptibility remains poorly characterized. OBJECTIVES AND METHODS: To identify the influence of coincident diabetes mellitus on cytokine levels in pulmonary tuberculosis, we examined circulating levels of a panel of cytokines and chemokines in the plasma of individuals with tuberculosis with diabetes and compared them with those of individuals without diabetes. MEASUREMENTS AND MAIN RESULTS: Tuberculosis with diabetes is characterized by elevated circulating levels of type 1 (IFN-γ, tumor necrosis factor-α, and IL-2), type 2 (IL-5), and type 17 (IL-17A) cytokines but decreased circulating levels of IL-22. This was associated with increased systemic levels of other proinflammatory cytokines (IL-1β, IL-6, and IL-18) and an antiinflammatory cytokine (IL-10) but not type 1 IFNs. Moreover, tuberculosis antigen-stimulated whole blood also showed increased levels of proinflammatory cytokines. Finally, type 1 and type 17 cytokines in plasma exhibit a significant positive correlation with hemoglobin A1C levels, indicating that impaired control of diabetes is associated with this proinflammatory milieu. Multivariate analysis revealed that the association of proinflammatory cytokines with diabetes mellitus was not influenced by age, sex, or other metabolic parameters. CONCLUSIONS: Our data reveal that tuberculosis with diabetes is characterized by heightened cytokine responsiveness, indicating that chronic inflammation underlying type 2 diabetes potentially contributes to increased immune pathology and poor control in tuberculosis infection.
RATIONALE: Type 2 diabetes mellitus is a major risk factor for the development of active tuberculosis, although the biological basis underlying this susceptibility remains poorly characterized. OBJECTIVES AND METHODS: To identify the influence of coincident diabetes mellitus on cytokine levels in pulmonary tuberculosis, we examined circulating levels of a panel of cytokines and chemokines in the plasma of individuals with tuberculosis with diabetes and compared them with those of individuals without diabetes. MEASUREMENTS AND MAIN RESULTS:Tuberculosis with diabetes is characterized by elevated circulating levels of type 1 (IFN-γ, tumor necrosis factor-α, and IL-2), type 2 (IL-5), and type 17 (IL-17A) cytokines but decreased circulating levels of IL-22. This was associated with increased systemic levels of other proinflammatory cytokines (IL-1β, IL-6, and IL-18) and an antiinflammatory cytokine (IL-10) but not type 1 IFNs. Moreover, tuberculosis antigen-stimulated whole blood also showed increased levels of proinflammatory cytokines. Finally, type 1 and type 17 cytokines in plasma exhibit a significant positive correlation with hemoglobin A1C levels, indicating that impaired control of diabetes is associated with this proinflammatory milieu. Multivariate analysis revealed that the association of proinflammatory cytokines with diabetes mellitus was not influenced by age, sex, or other metabolic parameters. CONCLUSIONS: Our data reveal that tuberculosis with diabetes is characterized by heightened cytokine responsiveness, indicating that chronic inflammation underlying type 2 diabetes potentially contributes to increased immune pathology and poor control in tuberculosis infection.
Authors: Mark S Wilson; Carl G Feng; Daniel L Barber; Felix Yarovinsky; Allen W Cheever; Alan Sher; Michael Grigg; Mary Collins; Lynette Fouser; Thomas A Wynn Journal: J Immunol Date: 2010-03-10 Impact factor: 5.422
Authors: Bianca E Schneider; Daniel Korbel; Kristine Hagens; Markus Koch; Bärbel Raupach; Jana Enders; Stefan H E Kaufmann; Hans-Willi Mittrücker; Ulrich E Schaible Journal: Eur J Immunol Date: 2010-02 Impact factor: 5.532
Authors: J E Stalenhoef; B Alisjahbana; E J Nelwan; J van der Ven-Jongekrijg; T H M Ottenhoff; J W M van der Meer; R H Nelwan; M G Netea; R van Crevel Journal: Eur J Clin Microbiol Infect Dis Date: 2007-10-26 Impact factor: 3.267
Authors: Blanca I Restrepo; Susan P Fisher-Hoch; Paula A Pino; Adrian Salinas; Mohammad H Rahbar; Francisco Mora; Nicolas Cortes-Penfield; Joseph B McCormick Journal: Clin Infect Dis Date: 2008-09-01 Impact factor: 20.999
Authors: Nathella P Kumar; Rathinam Sridhar; Dina Nair; Vaithilingam V Banurekha; Thomas B Nutman; Subash Babu Journal: Immunology Date: 2015-04 Impact factor: 7.397
Authors: S E Medellín-Garibay; N Cortez-Espinosa; R C Milán-Segovia; M Magaña-Aquino; J M Vargas-Morales; R González-Amaro; D P Portales-Pérez; S Romano-Moreno Journal: Antimicrob Agents Chemother Date: 2015-10-05 Impact factor: 5.191
Authors: V Mave; S Meshram; R Lokhande; D Kadam; S Dharmshale; R Bharadwaj; A Kagal; N Pradhan; S Deshmukh; S Atre; T Sahasrabudhe; M Barthwal; S Meshram; A Kakrani; V Kulkarni; S Raskar; N Suryavanshi; R Shivakoti; S Chon; E Selvin; A Gupte; A Gupta; N Gupte; J E Golub Journal: Int J Tuberc Lung Dis Date: 2017-12-01 Impact factor: 2.373
Authors: Katharina Ronacher; Reinout van Crevel; Julia A Critchley; Andrew A Bremer; Larry S Schlesinger; Anil Kapur; Randall Basaraba; Hardy Kornfeld; Blanca I Restrepo Journal: Chest Date: 2017-04-20 Impact factor: 9.410